J, S., A, S., M, H., M, R., R, E., M, S., . . . F, B. (2022). MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. Blood advances, 6(2), 515. https://doi.org/10.1182/bloodadvances.2021005532
Chicago Style (17th ed.) CitationJ, Stroh, et al. "MCT1 Is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma." Blood Advances 6, no. 2 (2022): 515. https://doi.org/10.1182/bloodadvances.2021005532.
MLA (9th ed.) CitationJ, Stroh, et al. "MCT1 Is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma." Blood Advances, vol. 6, no. 2, 2022, p. 515, https://doi.org/10.1182/bloodadvances.2021005532.
Warning: These citations may not always be 100% accurate.
